middle.news
Alterity Clears Key FDA Hurdle as ATH434 Heads Toward Phase 3
11:39am on Friday 30th of October, 2026 AEDT
•
Biotechnology
Read Story
Alterity Clears Key FDA Hurdle as ATH434 Heads Toward Phase 3
11:39am on Friday 30th of October, 2026 AEDT
Key Points
FDA alignment on a single pivotal Phase 3 trial plus confirmatory evidence
Approximately 200-patient study planned for ATH434 in Multiple System Atrophy
New US composition of matter patent extends protection to 2045
A$41.3 million cash balance after option proceeds and R&D tax refund
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE